Results 131 to 140 of about 92,514 (295)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Zonal Winds in Titan’s Middle Atmosphere from a Stellar Occultation Observed with Keck Adaptive Optics

The Planetary Science Journal
We present spatially resolved Keck/NIRC2 images of a stellar occultation by Titan on 2022 September 5 and compare them to predictions from concurrent Atacama Large Millimeter/submillimeter Array (ALMA) observations and a suite of general circulation ...
Theresa C. Marlin, Eliot F. Young, Katherine de Kleer, Martin Cordiner, Nicholas A. Lombardo, Imke de Pater, Juan M. Lora, Paul Corlies, Richard Cosentino, Conor Nixon, Sébastien Rodriguez, Alexander Thelen   +11 more
doaj   +1 more source

Wind and Eruptive Mass Loss near the Eddington Limit

Galaxies
Luminous, hot, massive stars can lose mass both through quasi-steady winds driven by line-scattering of the star’s continuum luminosity, and through transient eruptions identified as Luminous Blue Variables (LBVs).
Stan Owocki
doaj   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Obscuring Supersoft X-ray Sources in Stellar Winds [PDF]

, 2011
Mikkel Nielsen, C. Dominik, G. Nelemans
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Investigation for Binary Characteristics of LS I + 61°303 with Optical Polarization

The Astrophysical Journal
We investigate the optical linear polarization caused by Thomson scattering of the stellar radiation for gamma-ray binary LS I + 61°303, which likely contains a young pulsar.
Jiaxin Liu, Haoyu Yuan, Xiangli Lei, Wenlong Xu, Jumpei Takata, Weihua Lei   +5 more
doaj   +1 more source

Disruption of the Orion molecular core 1 by wind from the massive star θ¹ Orionis C. [PDF]

Nature, 2019
Pabst C, Higgins R, Goicoechea JR, Teyssier D, Berne O, Chambers E, Wolfire M, Suri ST, Guesten R, Stutzki J, Graf UU, Risacher C, Tielens AGGM.   +12 more
europepmc   +1 more source

The effects of stellar winds and magnetic fields on exoplanets [PDF]

, 2013
A. A. Vidotto
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source